Gabapentin Alternatives in South Carolina
Compare generic and therapeutic alternatives to Gabapentin (gabapentin) available at South Carolina pharmacies. Save up to 88% on your prescription — no insurance required.
Top Alternatives in South Carolina
Pregabalin (generic Lyrica)
therapeutic
Successor to gabapentin — more predictable absorption, slightly higher cost
Avg cash price: $40/mo
Duloxetine (generic Cymbalta)
therapeutic
SNRI effective for neuropathic pain — different mechanism
Avg cash price: $20/mo
Neurontin (brand gabapentin)
brand
Brand name — identical drug at 40× the cost
Avg cash price: $400/mo
South Carolina Prescription Assistance Programs
South Carolina Medicaid Rx (Healthy Connections)
Prescription drug coverage for South Carolina Medicaid (Healthy Connections) beneficiaries.
Eligibility: Low-income South Carolina children, pregnant women, seniors, and people with disabilities. South Carolina has not expanded Medicaid, limiting adult coverage.
Frequently Asked Questions
Is gabapentin the same as Neurontin?
Yes — gabapentin is the generic name for Neurontin. It has been generic since 2004 and costs $8–$14/month. Brand Neurontin can exceed $400/month.
Is gabapentin a controlled substance?
Gabapentin is not federally scheduled as a controlled substance in the US, but several states classify it as Schedule V due to misuse potential. Check your state's regulations.
How does gabapentin compare to pregabalin for nerve pain?
Pregabalin (Lyrica) has more predictable and complete absorption than gabapentin. Both are effective for neuropathic pain; gabapentin is much cheaper. Your doctor may start with gabapentin and switch if needed.
Can gabapentin be used for anxiety?
Gabapentin is prescribed off-label for social anxiety disorder and generalised anxiety, particularly in patients who have not responded to SSRIs. This is not an FDA-approved indication.
What does gabapentin cost through Script Unlock?
Gabapentin is among the most affordable medications — typically $8–$14/month. Script Unlock pharmacies can offer competitive cash pricing even at this already-low baseline.